List of Xepi drug patents
Xepi is owned by Ferrer Internacional.
Xepi contains Ozenoxacin.
Xepi has a total of 3 drug patents out of which 0 drug patents have expired.
Xepi was authorised for market use on 11 December, 2017.
Xepi is available in cream;topical dosage forms.
Xepi can be used as treatment of impetigo due to staphylococcus aureus or streptococcus pyogenes.
Drug patent challenges can be filed against Xepi from December, 2021.
The generics of Xepi are possible to be released after 29 January, 2032.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US6335447 | FERRER INTERNACIONAL | Quinolonecarboxylic acid derivatives or salts thereof |
Nov, 2023
(9 months from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9399014 | FERRER INTERNACIONAL | Pharmaceutical topical compositions |
Dec, 2029
(6 years from now) | |
| US9180200 | FERRER INTERNACIONAL | Pharmaceutical topical compositions |
Jan, 2032
(8 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Dec 11, 2022 |
Drugs and Companies using OZENOXACIN ingredient
NCE-1 date: December, 2021
Market Authorisation Date: 11 December, 2017
Treatment: Treatment of impetigo due to staphylococcus aureus or streptococcus pyogenes
Dosage: CREAM;TOPICAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic